Published in Hepatitis Weekly, February 20th, 2006
This funding is expected to total EUR 1.3 million (US$1.56 million) over the next 3 years and will cover 30% of the research and development costs for this program.
The grant aims at strengthening the development of Transgene's vaccine candidate TG4040 (MVA-HCV), which is undergoing preclinical studies and should enter phase 1/2 trial by mid-2006 to treat patients non responding to standard therapy. The TG4040 development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly